OSTEOPOROSIS-RELATED FRACTURES: EVALUATING THE ROLE OF PHARMACOTHERAPY
FACULTY
Robert Lindsay, MD
Professor, Department of Medicine
Columbia-Presbyterian Medical Center
Chief of Medicine
Helen Hayes Hospital
West Haverstraw, NY
Electronic newsletter now available:
Pharmacologic Approaches to Prevent Osteoporosis-Related Fractures.
Read frequently asked questions submitted by your peers.
PURPOSE STATEMENT
Osteoporosis-Related Fractures: Evaluating the Role of Pharmacotherapy will evaluate clinical trial data to discuss the role of pharmacologic therapy in managing patients with, or at risk for, osteoporotic fractures.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Describe the mechanism of action of pharmacologic agents that prevent and treat osteoporosis.
- Discuss the route of administration, dosing schedule, efficacy and safety of various treatment options for vertebral and nonvertebral fractures.
- Elaborate on the results of trials investigating the combined and sequential use of these agents.
- Incorporate this information into individualized, evidence-based treatment plans for patients with osteoporosis.
TARGET AUDIENCE
Osteoporotic Fractures: Evaluating the Role of Pharmacotherapy is intended for primary healthcare professionals, including physicians, physician assistants, nurse practitioners, nurses, and pharmacists, as well as for other specialists and healthcare providers who are interested in the management of patients with osteoporosis.
ACCREDITATION INFORMATION
Expiration date: October 24, 2008
Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of
1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.
Pharmacists: 
1 contact hours (0.100 CEUs) of credit for pharmacists. This activity co-sponsored by Medical Education Collaborative, Inc. (MEC) and Med-IQ. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE #: Webcast - #815-999-07-043-H01. Newsletter - #815-999-07-044-H01. The program is designed for all pharmacists.
Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 CreditTM.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME.
Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Faculty Disclosure
Robert Lindsay, MD
Consulting fees/advisory boards: Wyeth
Fees received for promotional/non-CME activities: GlaxoSmithKline, Roche Laboratories Inc., Wyeth, sanofi-aventis, U.S., Eli Lilly and Company
Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.
All other employees of Med-IQ have no financial relationships to disclose.
MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.
Acknowledgement of Commercial Support
This CME/CE activity is supported by an educational grant from sanofi-aventis U.S., Dermik, and the Alliance for Better Bone Health (sanofi-aventis U.S. and Procter & Gamble Pharmaceuticals).